An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy.
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Delanzomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Cephalon
- 10 May 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 11 Feb 2013 According to European Clinical trials database, this study has been suspended temporarily.
- 01 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.